As Biogen continues to struggle with the fallout from the controversial approval of the Alzheimer’s drug Aduhelm, the company’s head of research and development will step down at the end of 2021.

Biopharma and life sciences companies are strengthening their leadership teams and boards, including a new CEO for SAGA Diagnostics.

Alex Gorsky, Johnson & Johnson’s longtime chief executive officer and chairman of the board of directors, is stepping down from those roles. Gorsky passes the reins to Joaquin Duato, who is vice chairman of the company’s executive committee.

Merck Chief Executive Officer Kenneth C. Frazier is stepping down from his role atop the helm of the pharma giant on June 30, 2021, after nearly 30 years with the company.

Merck & Co.

Merck acquired Maryland-based OncoImmune and the Covid-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.

Merck & Co. Inc.’s Roger Perlmutter, a force behind the success of the blockbuster cancer drug Keytruda, will retire after seven years at the helm of the company’s research and development division.

Recent personnel movement within the healthcare industry includes a new CEO for Scenic Biotech.

Akorn Inc. said the company’s chief executive officer would retire following the drugmaker’s inability to salvage a takeover deal with Germany’s Fresenius SE.

Citing structural simplification, Pfizer announced plans to cut the company’s global staffing by about 2 percent, primarily through voluntary layoffs and early retirement through the end of 2018 and early in 2019.

Novo Nordisk is in advanced talks to acquire assets to bolster the company’s struggling biopharma business after the drugmaker announced the hiring of an AstraZeneca executive to head the unit.